5 结语
这些便是2019冠状病毒病的治疗、起源与影响:好的,坏的、丑陋的。在我们创建这个非常重要的生物医学领域30年后,吉娜·科拉塔(GinaKolata)或其他人也许会利用这个平台,让我与威廉·弗兰奇·安德森(William FrenchAnderson)和弗朗西斯·柯林斯(Francis Collins)讨论基因疗法。 致谢罗盖(Peter K. LAW)系中国的国家特聘专家。本项工作获肌母细胞医学研究院(武汉)支持。 利益冲突声明作者声明本论文的发表不存在利益冲突。 参考文献[1] Sherwood Romer, A. (1945) Vertebrate Paleontology. Universityof Chicago Press, Chicago, IL, 687 p. [2] Hand, S.J., et al . (2009) Bats that Walk: A NewEvolutionary Hypothesis for the Terrestrial Behaviour of New Zealand’s EndemicMystacinids. BMC Evolutionary Biology, 9, 169.https://doi.org/10.1186/1471-2148-9-169 [3] Boulikas, T. (1998) Status of Gene Therapy in 1997:Molecular Mechanisms, Disease Targets, and Clinical Applications. Gene Therapy& Molecular Biology, 1, 1-172. [4] Coutarda, B., Valleb, C., de Lamballeriea, X., Canardb, B.,Seidahc, N.G. and Decroly, E. (2020) The Spike Glycoprotein of the NewCoronavirus 2019-nCoV Contains a Furinlike Cleavage Site Absent in CoV of theSame Clade. Antiviral Research, 176, Article ID: 104742. https://doi.org/10.1016/j.antiviral.2020.104742 [5] Kessler, D.A., Siegel, J.P., Noguchi, P.D., Zoon, K.C.,Feiden, K.L. and Woodcock, J. (1993) Regulation of Somatic Cell-Therapy andGene Therapy by the Food and Drug Administration. The New England Journal ofMedicine, 329, 1169-1173. https://doi.org/10.1056/NEJM199310143291607 [6] Law, P.K., Bertorini, T., Goodwin, T.G., Chen, M., Fang,Q.W., Li, H.J., et al . (1990) Dystrophin Production Induced by MyoblastTransfer Therapy in Duchenne Muscular Dystrophy. The Lancet, 336, 114-115. https://doi.org/10.1016/0140-6736(90)91628-N [7] Wikipedia (2013) William French Anderson. https://en.wikipedia.org/wiki/William_French_Anderson [8] Kolata, G. (1990) Cell Transplant Found Effective in MuscleDisease: Muscular Dystrophy Patient Showed Strength Increase in First Test. NewYork Times. [9] Law, P.K. (2016) Disease Prevention and Alleviation by HumanMyoblast Transplantation. Open Journal of Regenerative Medicine, 5, 25-43. https://doi.org/10.4236/ojrm.2016.52003 [10] Anderson, W.F. (1990) Editorial. The Beginning. Human GeneTherapy, 1, 371-372. https://doi.org/10.1089/hum.1990.1.4-371 [11] Anderson, W.F. (1992) Human Gene Therapy. Science, 256,808-813. https://doi.org/10.1126/science.1589762 [12] Anderson, W.F. (1995) Gene Therapy. Scientific American,273, 96. [13] Crystal, R.G. (1997) Transfer of Genes to Humans: EarlyLesions and Obstacles to Success. Science, 270, 404-410.https://doi.org/10.1126/science.270.5235.404 [14] Verma, I. and Somia, N. (1997) Gene Therapy—Promises,Problems and Prospects. Nature, 389, 239-242. https://doi.org/10.1038/38410 [15] Thomas, C.E., Ehrhardt, A. and Kay, M.A. (2003) Progress andProblems with the Use of Viral Vectors for Gene Therapy. Nature ReviewsGenetics, 4, 346-358. https://doi.org/10.1038/nrg1066 [16] Culver, K.W. (1996) The First Human Gene Therapy Experiment.In: Culver, K.W., Ed., Gene Therapy : A Primer for Physicians, Mary AnnLiebert, Inc., New York, 47-53. [17] Brenner, M.K. (1995) Human Somatic Gene Therapy: Progressand Problems. Journal of Internal Medicine, 237, 229-239. https://doi.org/10.1111/j.1365-2796.1995.tb01171.x [18] DeLisi, C. (1988) The Human Genome Project. AmericanScientist, 76, 488-493. [19] Venter, J.C., Adams, M.D., Myers, E.W., Li, P.W., Mural,R.J., Sutton, G.G., et al . (2001) The Sequence of the Human Genome. Science,291, 1304-1351. https://doi.org/10.1126/science.1058040 [20] Venter, D. (2003) A Part of the Human Genome Sequence.Science, 299, 1183-1184. https://doi.org/10.1126/science.299.5610.1183 [21] White House Press Release. Retrieved on 22 July 2006. [22] DeLisi, C. (2008) Meetings that Changed the World: Santa Fe1986: Human Genome Baby-Steps. Nature, 455, 876- 877.https://doi.org/10.1038/455876a [23] Collins, F. (2006) The Language of God: A Scientist PresentsEvidence for Belief. Free Press, New York. [24] Beardsley, T. (1990) Profile: Gene Doctor. W. FrenchAnderson Pioneers Gene Therapy. Scientific American, 263, 33. https://doi.org/10.1038/scientificamerican0890-33 [25] Culver, K.W., Osborne, W.R., Miller, A.D., Fleisher, T.A.,Berger, M., Anderson, W.F., et al . (1991) Correction of ADA Deficiency inHuman T Lymphocytes Using Retroviral-Mediated Gene Transfer. TransplantationProceedings, 23, 170-171. [26] Karlsson, S. (1991) Treatment of Genetic Defects inHematopoietic Cell Function by Gene Transfer. Blood, 78, 2481-2492. https://doi.org/10.1182/blood.V78.10.2481.2481 [27] Gonzaga-Jauregui, C., Lupski, J.R. and Gibbs, R.A. (2012)Human Genome Sequencing in Health and Disease. Annual Review of Medicine, 63,35-61. https://doi.org/10.1146/annurev-med-051010-162644 [28] Snyder, M., Du, J. and Gerstein, M. (2012) Personal GenomeSequencing: Current Approaches and Challenges. Genes & Development, 24, 423-431. https://doi.org/10.1101/gad.1864110 [29] Collins, F. (2020) Genomic Study Points to Natural Origin ofCOVID-19. NIH Director’s Blog. [30] Andersen, K.G., Rambaut, A., Lipkin, W.I., Holmes, E.C. andGarry, R.F. (2020) The Proximal Origin of SARS-CoV-2. Nature Medicine, 17. https://doi.org/10.1038/s41591-020-0820-9 [31] Law, P.K. (1992) Myoblast Transplantation. Science, 257,1329-1330. https://doi.org/10.1126/science.1529326 [32] Ren, W., Qu, X., Li, W., Han, Z., Yu, M., Zhou, P., Zhang,S.Y., Wang, L.F., Deng, H. and Shi, Z (2008) Difference in Receptor Usagebetween Severe Acute Respiratory Syndrome (SARS) Coronavirus and SARS-LikeCoronavirus of Bat Origin. Journal of Virology, 82, 1899-1907.https://doi.org/10.1128/JVI.01085-07 [33] Kuo, L., Godeke, G.J., Raamsman, M.J., Masters, P.S. andRottier, P.J. (2000) Retargeting of Coronavirus by Substitution of the SpikeGlycoprotein Ectodomain: Crossing the Host Cell Species Barrier. Journal ofVirology, 74, 1393-1406. https://doi.org/10.1128/JVI.74.3.1393-1406.2000 [34] Casais, R., Dove, B. Cavanagh, D. and Britton, P. (2003)Recombinant Avian Infectious Bronchitis Virus Expressing a Heterologous SpikeGene Demonstrates that the Spike Protein Is a Determinant of Cell Tropism.Journal of Virology, 77, 9084-9089. https://doi.org/10.1128/JVI.77.16.9084-9089.2003 [35] Haijema, B.J., Volders, H. and Rottier, P.J. (2003)Switching Species Tropism: An Effective Way to Manipulate the FelineCoronavirus Genome. Journal of Virology, 77, 4528-4538. https://doi.org/10.1128/JVI.77.8.4528-4538.2003 [36] de Haan, C.A., Kuo, L., Masters, P.S., Vennema, H. andRottier, P.J. (1998) Coronavirus Particle Assembly: Primary StructureRequirements of the Membrane Protein. Journal of Virology, 72, 6838-6850. https://doi.org/10.1128/JVI.72.8.6838-6850.1998 [37] Hou, Y., Peng, C., Yu, M., Li, Y., Han, Z., Li, F., Wang,L.-F. and Shi, Z. (2020) Angiotensin-Converting Enzyme 2 (ACE2) Proteins ofDifferent Bat Species Confer Variable Susceptibility to SARS-CoV Entry.Archives of Virology, 155, 1563-1569. https://doi.org/10.1007/s00705-010-0729-6 [38] Yu, M., Stevens, V., Berry, J.D., Crameri, G., McEachern,J., Tu, C., Shi, Z., Liang, G., Weingart, H., Cardosa, J., Eaton, B.T., Wang,L.F. (2008) Determination and Application of Immunodominant Regions of SARSCoronavirus Spike and Nucleocapsid Proteins Recognized by Sera from DifferentAnimal Species. Journal of Immunological Methods, 331, 1-12. https://doi.org/10.1016/j.jim.2007.11.009 [39] Tu, C., Crameri, G., Kong, X., Chen, J., Sun, Y., Yu, M.,Xiang, H., Xia, X., Liu, S., Ren, T., Yu, Y., Eaton, B.T., Xuan, H. and Wang,L.F. (2004) Antibodies to SARS Coronavirus in Civets. Emerging InfectiousDiseases Journal, 10, 2244-2248. https://doi.org/10.3201/eid1012.040520 [40] Yount, B., et al . (2003) Reverse Genetics with aFull-Length Infectious cDNA of Severe Acute Respiratory Syndrome Coronavirus.Proceedings of the National Academy of Sciences of the United States ofAmerica, 100, 12995-13000. https://doi.org/10.1073/pnas.1735582100 [41] Menachery, V.D., Yount Jr., B.L., Debbink, K., Agnihothram,S., Gralinski, L.E., Plante, J.A., Graham, R.L., Scobey, T., Ge, X.-Y.,Donaldson, E.F., Randell, S.H., Lanzavecchia, A., Marasco, W.A., Shi, Z.-L. andBaric, R.S. (2015) A SARS-Like Cluster of Circulating Bat Coronaviruses ShowsPotential for Human Emergence. Nature Medicine, 21, 1508-1513. https://doi.org/10.1038/nm.3985 [42] Kaiser, J. (2014) Moratorium on Risky Virology StudiesLeaves Work at 14 Institutions in Limbo. ScienceInsider. http://news.sciencemag.org/biology/2014/11/moratoriumrisky-virology-studies-leaves-work-14-institutions-limbo [43] Sheahan, T.P., Sims, A.C., Zho, S., Graham, R.L.,Pruijssers, A.J., Agostini, M.L., et al . (2020) An Orally BioavailableBroad-Spectrum Antiviral Inhibits SARS-CoV-2 in Human Airway Epithelial CellCultures and Multiple Coronaviruses in Mice. Science Translational Medicine.https://doi.org/10.1126/scitranslmed.abb5883 [44] Law, P.K. (2020) Emergent Serum Therapy and AntibodyMedicine to Counteract Sudden Attacks of COVID-19 and Other PathogenicEpidemics. Open Journal of Regenerative Medicine, 9, 1-7. https://www.scirp.org/journal/ojrm https://doi.org/10.4236/ojrm.2020.91001 [45] Law, P.K. (2020) System Engineering of Emergent SerumTherapy to Combat COVID-19 and Other Pathogenic Pandemics Open Journal ofRegenerative Medicine, 9, 8-14. https://doi.org/10.4236/ojrm.2020.91002 [46] Millet, J.K. and Whittaker, G.R. (2014) Host Cell Entry ofMiddle East Respiratory Syndrome Coronavirus after Two-Step, Furin-MediatedActivation of the Spike Protein. Proceedings of the National Academy ofSciences of the United States of America, 111, 15214-15219. https://doi.org/10.1073/pnas.1407087111 [47]https://www.infowars.com/full-transcript-of-smoking-gun-bombshell-interview-prof-francis-boyle-exposes-the-bioweapons-origin-of-the-covid-19-corona-virus [48] Law, P.K. (2017) Crime against Humanity. Open Journal ofRegenerative Medicine, 6, 35-45. https://doi.org/10.4236/ojrm.2017.64004 [49] Stennes, M.L. (1997) The Criminalization of Innovation: FDAMisdirection in the Najarian and Burzynski Cases (1997 Third Year Paper).Harvard Law School. http://nrs.harvard.edu/urn-3:HUL.InstRepos:9453691 [50] Seife, C. (2016) FDA Documents Reveal Depths of InternalRancor over Drug’s Approval Process. Undark.https://undark.org/article/fda-eteplirsen-janet-woodcock/ [51] Law, P.K., et al (2019) Myoblasts Provide Safe and EffectiveTreatments for Hereditary Muscular Dystrophies, Cardiomyopathies, Type 2Diabetes, Solid Tumors and Aging. In: Haider, K.H. and Aziz, S., Eds., StemCells—From Hype to Real Hope, Walter de Gruyter GmbH, Berlin, 71-97. https://doi.org/10.1515/9783110587043-004 [52] Schoofs, T., Klein, F., Braunschweig, M., et al . (2016)HIV-1 Therapy with Monoclonal Antibody 3BNC117 Elicits Host Immune Responsesagainst HIV-1. Science, 352, 997-1001. https://doi.org/10.1126/science.aaf0972 [53] Lu, C.L., Murakowski, D.K., Bournazos, S., et al . (2016)Enhanced Clearance of HIV-1-Infected Cells by Broadly Neutralizing Antibodiesagainst HIV-1 in Vivo. Science, 352, 1001-1004. https://doi.org/10.1126/science.aaf1279 [54] ter Meulen, J., van den Brink, E.N., Poon, L.L.M., et al .(2006) Human Monoclonal Antibody Combination against SARS Coronavirus: Synergyand Coverage of Escape Mutants. PLoS Medicine, 3, e237. https://doi.org/10.1371/journal.pmed.0030237 [55] ter Meulen, J., Bakker, A.B., van den Brink, E.N., et al .(2004) Human Monoclonal Antibody as Prophylaxis for SARS Coronavirus Infectionin Ferrets. The Lancet, 363, 2139-2141.https://doi.org/10.1016/S0140-6736(04)16506-9 [56] Chu, C., Cheng, V., Hung, I., et al . (2004) Role ofLopinavir/Ritonavir in the Treatment of SARS: Initial Virological and ClinicalFindings. Thorax, 59, 252-256. https://doi.org/10.1136/thorax.2003.012658 [57] Chan, K.S., Lai, S.T., Chu, C.M. et al . (2003) Treatment ofSevere Acute Respiratory Syndrome with Lopinavir/Ritonavir: A MulticentreRetrospective Matched Cohort Study. Hong Kong Medical Journal, 9, 399-406. [58] Clark, D.R., Jonathan, E.M., et al . (2020) ClinicalEvidence Does Not Support Corticosteroid Treatment for 2019-nCoV Lung Injury.The Lancet . [59] WHO (2020) Clinical Management of Severe Acute RespiratoryInfection When Novel Coronavirus (nCoV) Infection Is Suspected. https://www.who.int/docs/default-source/coronaviruse/clinical-management-of-novel-cov.pdf [60] Lee, N., Chan, A., Hui, K.C., et al . (2004) Effects ofEarly Corticosteroid Treatment on Plasma SARS-Associated Coronavirus RNAConcentrations in Adult Patients. Journal of Clinical Virology, 31, 304-309. https://doi.org/10.1016/j.jcv.2004.07.006 [61] Vincent, M.J., Bergeron, E., Benjannet, S., et al . (2005)Chloroquine Is a Potent Inhibitor of SARS Coronavirus Infection and Spread.Virology Journal, 2, 69. https://doi.org/10.1186/1743-422X-2-69 [62] Bin, J., Qi, Z., Ge, X., Wang, R., Yu, J., Shan, S., et al .(2020) Potent Human Neutralizing Antibodies Elicited by SARS-CoV-2 Infection.BioRxiv Preprint. [63] Holshue, M.L., DeBolt, C., Lindquist, S., et al . (2020)First Case of 2019 Novel Coronavirus in the United States. The New EnglandJournal of Medicine, 382, 929-936. https://doi.org/10.1056/NEJMoa2001191 [64] Mair-Jenkins, J., Saavedra-Campos, M., Baillie, J.K., et al. (2015) The Effectiveness of Convalescent Plasma and HyperimmuneImmunoglobulin for the Treatment of Severe Acute Respiratory Infections ofViral Etiology: A Systematic Review and Exploratory Meta-Analysis. The Journalof Infectious Diseases, 211, 80-90. https://doi.org/10.1093/infdis/jiu396 [65] Chen, L., Xiong, J., Bao, L. and Shi, Y. (2020) ConvalescentPlasma as a Potential Therapy for COVID-19. The Lancet Infectious Diseases. https://doi.org/10.1016/S1473-3099(20)30141-9 [66] Zhou, J., Chu, H., Li, C., et al . (2014) Active Replicationof Middle East Respiratory Syndrome Coronavirus and Aberrant Induction ofInflammatory Cytokines and Chemokines in Human Macrophages: Implications forPathogenesis. The Journal of Infectious Diseases, 209, 1331-1342. https://doi.org/10.1093/infdis/jit504 [67] Lai, S.T. (2005) Treatment of Severe Acute RespiratorySyndrome. European Journal of Clinical Microbiology & Infectious Diseases,24, 583-591. https://doi.org/10.1007/s10096-005-0004-z [68] Soo, Y.O., Cheng, Y., Wong, R., et al . (2004) RetrospectiveComparison of Convalescent Plasma with Continuing High-Dose MethylprednisoloneTreatment in SARS Patients. Clinical Microbiology and Infection, 10, 676-678. https://doi.org/10.1111/j.1469-0691.2004.00956.x [69] Cheng, Y., Wong, R., Soo, Y.O., et al . (2005) Use ofConvalescent Plasma Therapy in SARS Patients in Hong Kong. European Journal ofClinical Microbiology & Infectious Diseases, 24, 44-46.https://doi.org/10.1007/s10096-004-1271-9 [70] Chippaux, J.-P., Boyer, L.V. and Alagón, A. (2015)Post-Exposure Treatment of Ebola Virus Using Passive Immunotherapy: Proposalfor a New Strategy. Journal of Venomous Animals and Toxins including TropicalDiseases, 21, 3. https://doi.org/10.1186/s40409-015-0003-1 |
E_mail: redchinacn@gmail.com
2010-2011http://redchinacn.net